I have genetics on the brain, so yes: I definitely think that data from both germline GWAS and somatic variation studies can be valuable for drug discovery. We don’t work on antibodies at Recursion today (though we have piloted them and they worked great on the platform), but we certainly make use of genetics data to inform our directions. As far as canonical targets, our platform allows us to be agnostic and to explore without having to select a target. As we move through our drug discovery process we aim to understand as much as possible about the target and its mechanism of action.